ghk-cu 50 – Research Peptide GHK-Cu - Simon's Compounding

The study looked at whether a combination of cardiovascular outcomes (heart attack, stroke, cardiac death, mini-stroke, urgent heart surgery for coronary disease) were more common in the allopurinol or the febuxostat group

(12) Xiaoxiao Mu, Lijun Qu, Liquan Yin, Libo Wang, et al (2024) Pichia pastoris secreted peptides crossing the blood-brain barrier and DSIP fusion peptide efficacy in PCPA-induced insomnia mouse models Frontiers in Pharmacology, ALL CONTENT AND PRODUCT INFORMATION AVAILABLE ON THIS WEBSITE IS FOR EDUCATIONAL PURPOSES ONLY

That said, the combination itself has not been clinically validated there are no controlled human trials of this specific blend, and the supporting data for each peptide is largely preclinical (animal) work and anecdote

No significant toxicity indicators reported during the preclinical trials

This raises questions about dosage adjustments over time that the standard escalation charts do not address